

MEDICAL UNIVERSITY - PLEVEN FACULTY OF MEDICINE

DEPARTMENT OF PEDIATRICS

Lecture № 13

CHRONIC LUNG INFLAMMATION. CYSTIC FIBROSIS

Assoc. Prof. Dr. Rada Markova

First Pediatric Consultative Clinic - Sofia Medical University - Pleven



LUNG INFLAMMATION

- Acute lung inflammation (acute pneumonia) duration up to 3 weeks
- Protracted pneumonia 6-8 weeks
- Recurrent pneumonia 3 and more times at the same place
- Chronic pneumonia duration more than 3 months



CHRONIC PNEUMONIA

- Chronic lung inflammation with non —reversible morphologic parenchymal changes in a particular lung segment or lobe - fibrosis and pneumosclerosis with intermittent exacerbation and remission
- Exclusion of all diffuse and extending lung diseases in systemic or congenital disorders like: hemosiderosis, mucoviscidosis, etc, and also exclusion of the specific lung inflammation, typical for tuberculosis
- Some data show equivalence between chronic pneumonia and bronchiectasis



CHRONIC PNEUMONIA (CP)

- Incidence of CP 1-3% of children with pulmonary diseases, more often in school age
- Etiology of CP: secondary disease after a protracted or acute pneumonia: acute pneumonia in neonatal or early infant period, BPD, foreign body aspiration, congenital lung abnormalities, immune deficiency disorders, GER, rickets, hypotrophia, after measles and pertussis
- Microbiology characteristics of CP: mixed microbial flora
- Pathogenesis of CP: impaired bronchial drainage purulent endobronchitis lung destruction pronchiectasis chronic lung failure and cor pulmonale



CHRONIC PNEUMONIA

Clinical characteristics:

- ✓ Cough- persistent, in the mornings, wet, with a lot of muco-purulent flam
- ✓ Change of external appearance-paleness, failure to thrive
- ✓ Chronic hypoxia : changes of the nails, cor pulmonale
- ✓ Auscultation: bronchitis: wheezing or wet crackles, localized
- ✓ "Middle lobe" syndrome



CHRONIC PNEUMONIA

- X-ray: "Honeycomb" image: atelectasis, emphysema, fibrosis
- Bronchoscopy, bronchography
- Lab parameters, microbiology
- PFT test restrictive pulmonary failure

Evolution: chronic course: remission and exacerbation

DD: TBC, CF, protracted pneumonia, interstitial fibrosis, etc.

Treatment: - mucolytics, antibiotics, inhalations, physiotherapy


- lung operation in case of local bronchiectasis



KARTAGENER SYNDROME

- Triade: situs viscerus inversus+bronchiectasis+pansinuitis
- ARD genetic disease, incidence: 1:1 500 -1:30 000
- Pathophysiology: ciliar dyskinesia due to a loss of dynein protein in cilia impaired muco-ciliar transport
- Cilia defect affects middle ear, sinuses and bronchi, also spermatozoids
- Clinical symptoms: chest deformities, cough (wet and deep), heart pick in the right chest part, failure to thrive, nasal polyps, purulent nasal secretions, dyspnea, etc.






KARTAGENER SYNDROME

- X ray: inverted organs, diffuse changes into lung bases
- PFT restrictive and obstructive lung changes
- Low levels of IgA
- FBS, MRI
- DD: dextrocardia, s-me Chandra Khetarpal, s-me Turpin, etc.
- Treatment: complex treatment: bronchial drainage, mucolitics, antibiotics, etc.



PRIMARY CILIARY DYSKINESIA (PCD)

- Abnormal ciliar function and structure, impaired bronchial drainage, recurrent sino
 pulmonal disease
- Incidence: 1:40000
- ARD disorder, defect of dineyn synthesis
- PCD is associated with situs inversus, liver and kidney cysts, biliary atresia and bronchiectasis








PCD

- Infection of lower respiratory tract, chronic cough, muco-purulent secretions, wheezing, dyspnea
- Chronic rhinitis, sinusitis, middle ear infection
- Diagnostic tests: screening tests: nasal NO, saccharin test, electron microscopy
- Colonization: H. influenzae, Ps. Aeruginosa, S. aureus, S. pneumoniae
- Treatment: aggressive treatment of exacerbations: antibiotics (oral + inhaled), mucolytics, inhalations













EOSINOPHILIC PNEUMONIA (EP)

- Eo infiltration in the lung interstitium and alveoli
- EP can be primary (idiopathic) or secondary (due to specific medications of ABPA, tumors, etc.)
- EP can be acute or chronic in course
- Loffler syndrome is a rare case of EP, pulmonary failure, Eo migrating infiltrates, blood Eo
- Idiopathic acute and chronic EP: cough, fatigue, chest pain, arthralgias, myalgias, blood Eo, atopy, BLA with Eo infiltration
- Churg Strauss syndrome: vasculitis of the small and medium vessels with Triade: asthma, allergic rhinitis, hyper Eo



CHURG-STRAUSS SYNDROME

3 Clinical phases

Prodromal Phase

- Late onset allergic rhinitis and atopy*
- Lasting for >10 years

Eosinophilic phase

- Marked blood eosinophilia
- Eosinophillic infiltration of lung, GI tract or skin

Vasculitic phase

- Vasculitis of the small and medium vessels
- Vascular and extravascular granulomas
- Constitutional symptoms
- Worsening asthma symptoms




PULMONARY ALVECLAR PROTEINOSIS (PAP)

- Described by Rosen in 1958 Castleman- microscopic changes into the alveoli,
 PAS positive
- PAP could be congenital or acquired
- Congenital PAP: neonatal RDS, autosomal recessive disorder(ARD), disturbance of surfactant metabolism: SP-B, SP-C. This form can be diagnosed by a gene diagnosis, BAL analysis, high LDH level
- Acquired PAP: non productive cough, dyspnea, cyanosis, chest pain, hemoptoe, failure to thrive, reduced weight
- Treatment of PAP: bronchial lavage, gene therapy, lung transplantation



PAP




Pulmonary Alveolar Proteinosis




diffuse reticulo-alveolar infiltrates BAT WING distribution

BAL:- milky effulent foamy macrophages with lipoproteinous intraalveolar material

thickened interlobular septa "crazy paving" ground glass fashion, sharply demarked from normal lung creating a "geographic" pattern.



PULMONARY HEMOSIDEROSIS



- Primary disease, hypersensitivity to a cow milk (immune response), or combination with nephritis (Goodpasture syndrome)
- Clinical findings: attacks of pulmonary interstitial hemorrhages + hypochromic microcytic anemia with low serum iron
- Contract of minimal physical findings with severe general condition and deterioration, followed by respiratory failure
- In severe crisis a hemorrhage shock could be observed, also jaundice and HSM
- Pulmonary X ray: perihilar infiltrates, atelectasis, adenopathy, emphysema, PFT restriction
- Diagnosis: hemosiderophages in sputum and BAL, typical clinical and lab
- Treatment: oxygen, hemotrasfusions, CS, Desferal, poor prognosis



IDIOPATHIC PULMONARY FIBROSIS

- Also called Hamman Rich syndrome
- Unclear etiology, rare in childhood
- Clinical symptoms: dyspnea, cough, tachypnea, cyanosis, chronic cor pulmonale
- Physical examination is insufficient ,X ray: interstitial infiltrates mainly in the lung bases
- No specific treatment, poor prognosis

In the group of chronic lung diseases also must be pointed: pulmonary alveolar microlithiasis and alfa 1- AT deficiency



CYSTIC FIBROSIS

- Incidence: cystic fibrosis (CF) is the most frequent lethal genetic disorder in white people, 1: 3000 for white race, 1:10 000 hispano Americans, 1:20 000 African people
- ARD, 7q-chromosome CFTR, over 1600 mutations, more than 50% delta F508, six classes of CFTR mutations
- No correlation between genotype and phenotype, genotype is connected only with pancreatic sufficiency
- CFTR gene is cloned in 1989, also important the role of modifying genes



CYSTIC FIBROSIS

- Pathophysiology: "low volume" hypothesis: reabsorption of sodium, decreased secretion of chloride passive H₂O movement surface dehydration impaired microcellular clearance bacterial invasion (S.aureus, H influenzae, Ps. Aeruginosa)
- Affected organs: skin, exocrine pancreas, gastro-intestinal tract, reproductive system, respiratorysystem
- Secondary involved : endocrine pancreas, muscle and bones, CNS, kidneys, etc.



DIAGNOSIS OF CF

- Middle age of diagnosis: 6 months
- Clinical symptoms: respiratory symptoms 50%, malnutrition and failure to thrive 34%, diarrhea 26%, meconium ileus 21%, family history 16%, metabolic alkalosis
- Neonatal screening (since 2008) IRT
- Sweat test: positive above 60 mmol/l, negative below 30(40), borderline: 30-60 mmol/l
- Sweat test could be false positive or false negative!!!
- Fecal elastase <100 mcg
- Steatorrhea
- Genetic test ,NPD



CF — CLINICAL SYMPTOMS — MULTIORGAN DISEASES

- A. Respiratory system :
- ✓ URA: chronic sinusitis, nasal polyposis
- ✓ LRA: chronic pneumonia, bronchiectasis, wheezing
- ✓ Complications: atelectasis, pneumothorax, hemoptysis, ABPA, respiratory failure, cor pulmonale
- ✓ Typical bacterial agents: S.aureus, H.influenzae, Ps. Aeriginosa, Stenotrophomonas maltophilia, Burkhordelia sepacia, non TBC mycobacteria, Aspergillus fumigatus




CF — PULMONARY COMPLICATIONS

- In FEV1<30%, PaO2<55 mm, PaCO2>50 mm end stage of the disease lung transplantation
- Clinical symptoms up to the age of 1 year :

wheezing bronchitis with difficult treatment,


than - recurrent pneumonias, after 3 yeas of life: bronchiectasis






CF LUNGS









CF — CLINICAL MANIFESTATIONS

B. GI manifestation

- ✓ Meconium ileus at birth- 15%
- ✓ Rectal prolapse
- ✓ More than 90% pancreas insufficiency: steatorrhea, flatulence, failure to thrive, diarrhea, malnutrition and vit.deficinecy
- ✓ Distal obstructive syndrome (DIOS)
- ✓ Low vit A, D, E, K anemia, neuropathy, osteoporosis, bleeding, poor night sight, etc.
- **✓**GERD
- ✓ Pancreatitis, biliary cirrhosis



CF — CLINICAL MANIFESTATIONS

C. Electrolyte disturbances

- ✓ Hypo K+
- ✓ Hypo Na+
- ✓ Metabolic alkalosis
- ✓ Hypotonic dehydration

D. Reproductive problems:

- ✓ Azoospermia, congenital occlusion of vas deference
- √ Thick cervical mucous in females



CF- CLINICAL MANIFESTATIONS

E. Other symptoms:

✓Impaired glucose tolerance, diabetes mellitus: annually blood sugar and oral glucose tolerance test.


Diabetes is with low insulin secretion, ketoacidosis is quite rare.

No immune mechanism, no antibodies.

✓ Osteoporosis due to low vit D, chronic inflammation, steroid usage



CYSTIC FIBROSIS (CF)





CF — TREATMENT : CF CENTERS

- 1. Pancreatic enzyme replacement therapy:
- 500 2000 U/kg lipase per meal
- Fat dissolved vitamins
- Ursofalk 20 mg/kg/day
- Increase salt intake
- Monitoring of BW, BH, BMI



CF TREATMENT

2. Pulmonary treatment

a/Bronchial obstruction

- Clearance of bronchial tree, drainage, PEP mask, Vest method, "Flutter"
- Bronchodilators: in 25% of CF patients are used without stopping, or in need
- Pulmozyme (Dornase alfa) after 5 year of age, improves mucocilliar transport
- Hypertonic (3-6-7%) saline water solution



CF TREATMENT

b/Pulmonary infections

- AB courses with high doses and duration 14-21 days
- Inhalatory options: Colistin, Tobramycin, Amikacin
- Oral courses
- Intravenous courses : anti Pseudomonas groups
- Mucolytics

c/ Anti- inflammatory medications

- Corticosteroids: Systemic and inhaled
- Ibuprofen
- Macrolydes




CF FOLLOW UP

- Physical examination : every 3 months
- Spirometry: 2-4 times per year
- Microbiology specimen every 3 months
- Lab parameters every 6 months
- X ray in need, CT scan, MRI
- New biological treatment target therapy



TARGET THERAPY OF CF





Thank you for your attention!

